266P - Tumor characteristics, treatment and overall survival (OS) in breast cancer patients (pts) over 80 years: a cohort from a single institution

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Breast Cancer, Early Stage
Geriatric Oncology
Presenter Capucine Baldini
Authors C. Baldini1, A. Donnadieu1, A. Kramar2, V. Servent1, J. Bonneterre3
  • 1Breast Cancer, Centre Oscar Lambret, 59000 - Lille/FR
  • 2Biostatistics, Centre Oscar Lambret, 59000 - Lille/FR
  • 3Centre Oscar Lambret, Université Lille Nord de France, 59000 - Lille/FR

Abstract

The incidence rate of breast cancer in elderly women over 75 years old is 220 per 100000 in France and is likely to increase in the future. We studied the impact of tumor and treatment characteristics on overall survival.

Patients and methods

Data were collected for 208 non metastatic breast cancer pts over 80 years (213 tumors), treated from January 2000 to December 2009. Pathological data were obtained on a biopsy or on mastectomy specimens if patients had not received presurgical treatment.

Statistical methods

Survival rates were estimated by Kaplan-Meier method. Tests were performed with the logrank test. Five year relative survival rates were estimated by Ederer2 method.

Results

Median age at diagnosis was 83 years (80-95). 29% tumors were T1, 58% T2 and 15% T3, 141 (66%) were ductular, 34 (16%) lobular and 38 (18%) had another histological type. SBR grade (I/II/III) was 22%/49%/29% and unspecified in 42 (20%). 167 pts (80%) were ER + , 129 (62%) PR + ; 40 (19%) ER–PgR–, and 171 (81%) ER + PgR+. HER2 status, known in 126 pts, was positive in 18 (14%), and negative in 108 (86%). Ten pts were strictly triple negative (5%)(ER = 0, PgR = 0, HER2 = 0). Ki 67 among 59 tumors was over 15% in 43 pts (73%). Forty-nine pts (23%) had conservative surgery, 80 mastectomy (38%), 72 axillary dissection (34%) and 30 sentinel lymph node biopsy (14%). Axillary lymph node metastasis were observed in 52 pts (38%). 195 pts received hormonotherapy (68 as adjuvant therapy, 89 before surgery or alone), 72 patients radiotherapy (37%), 5 chemotherapy (3%) and 1 had trastuzumab (0.5%). Median overall survival was 59 months. Median follow up was 76 months. The only significant prognostic factors on overall survival were age (48 months over 83 years, 79 before), ER and PgR status. ER positive and negative pts had a median survival of 60 months and 32 months respectively. Five year relative survival rate was 63%.

Conclusion

Even if most pts had a ER+ tumor, the rate of poor prognosis factors is high: 29% SBR III, 14% HER2 positive, 5% triple negative and 73% had a KI67 index over 15%. Despite these poor prognostic factors, survival was rather long with a median OS of 5 years.

Disclosure

All authors have declared no conflicts of interest.